Drug Trial Radar · NCT07596485
RP-008 in Combination With Daily Oral Varenicline for the Treatment of Trigeminal Neuralgia
Last checked: Nov 20, 2026Latest source record: Oct 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
24
Planned (sponsor's estimate)
Start
Sep 10, 2026
Primary completion
Feb 2029
Study completion Feb 2029
Sponsor
- Lead sponsor
- Kriya Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- May 19, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this study is to evaluate if KRIYA-748 (RP-008) is safe, tolerable, and preliminary effective in treating trigeminal neuralgia (TN) when used in combination with varenicline tartrate. The study will also assess what doses of RP-008 are safe and tolerable for participants and how the severity of participants' TN pain and frequency of facial pain attacks are affected.
Conditions
- Trigeminal Neuralgia
Interventions
RP-008Genetic
RP-008 will be administered as a single percutaneous injection to the trigeminal ganglion.
Varenicline tartrateDrug
Varenicline tartrate will be administered as a daily oral tablet.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence and severity of adverse events, abnormal clinical laboratory values, abnormal physical examinations, abnormal vital signs, abnormal electrocardiograms (ECGs), and suicidal ideationTime frame: 12 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
University of Sherbrooke
Sherbrooke, Canada · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.